NCT06586580View on ClinicalTrials.gov

Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1

CompletedOBSERVATIONAL

Enrollment

18

Participants

Timeline

Start Date

March 30, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Metastatic Melanoma

Trial Locations (1)

Unknown

CHU de Besançon, Besançon

All Listed Sponsors

lead

Centre Hospitalier Universitaire de Besancon

OTHER